These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 11961667

  • 1. Transcription-targeted gene therapy for androgen-independent prostate cancer.
    Martiniello-Wilks R, Tsatralis T, Russell P, Brookes DE, Zandvliet D, Lockett LJ, Both GW, Molloy PL, Russell PJ.
    Cancer Gene Ther; 2002 May; 9(5):443-52. PubMed ID: 11961667
    [Abstract] [Full Text] [Related]

  • 2. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer.
    Xie X, Zhao X, Liu Y, Zhang J, Matusik RJ, Slawin KM, Spencer DM.
    Cancer Res; 2001 Sep 15; 61(18):6795-804. PubMed ID: 11559553
    [Abstract] [Full Text] [Related]

  • 3. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.
    Lowe SL, Rubinchik S, Honda T, McDonnell TJ, Dong JY, Norris JS.
    Gene Ther; 2001 Sep 15; 8(18):1363-71. PubMed ID: 11571575
    [Abstract] [Full Text] [Related]

  • 4. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
    Latham JP, Searle PF, Mautner V, James ND.
    Cancer Res; 2000 Jan 15; 60(2):334-41. PubMed ID: 10667585
    [Abstract] [Full Text] [Related]

  • 5. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors.
    Martiniello-Wilks R, Garcia-Aragon J, Daja MM, Russell P, Both GW, Molloy PL, Lockett LJ, Russell PJ.
    Hum Gene Ther; 1998 Jul 20; 9(11):1617-26. PubMed ID: 9694160
    [Abstract] [Full Text] [Related]

  • 6. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
    Hsieh CL, Gardner TA, Miao L, Balian G, Chung LW.
    Cancer Gene Ther; 2004 Feb 20; 11(2):148-55. PubMed ID: 14695756
    [Abstract] [Full Text] [Related]

  • 7. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells.
    Gadi VK, Alexander SD, Kudlow JE, Allan P, Parker WB, Sorscher EJ.
    Gene Ther; 2000 Oct 20; 7(20):1738-43. PubMed ID: 11083495
    [Abstract] [Full Text] [Related]

  • 8. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
    Gotoh A, Ko SC, Shirakawa T, Cheon J, Kao C, Miyamoto T, Gardner TA, Ho LJ, Cleutjens CB, Trapman J, Graham FL, Chung LW.
    J Urol; 1998 Jul 20; 160(1):220-9. PubMed ID: 9628654
    [Abstract] [Full Text] [Related]

  • 9. Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer.
    Lee SJ, Zhang Y, Lee SD, Jung C, Li X, Kim HS, Bae KH, Jeng MH, Kao C, Gardner T.
    Mol Ther; 2004 Dec 20; 10(6):1051-8. PubMed ID: 15564137
    [Abstract] [Full Text] [Related]

  • 10. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T, Lin FF, Rao P, Lin MF.
    Prostate; 2003 Jun 01; 55(4):247-58. PubMed ID: 12712404
    [Abstract] [Full Text] [Related]

  • 11. Prostate-tumor targeting of gene expression by lentiviral vectors containing elements of the probasin promoter.
    Yu D, Jia WW, Gleave ME, Nelson CC, Rennie PS.
    Prostate; 2004 Jun 01; 59(4):370-82. PubMed ID: 15065085
    [Abstract] [Full Text] [Related]

  • 12. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer.
    Li Y, McCadden J, Ferrer F, Kruszewski M, Carducci M, Simons J, Rodriguez R.
    Cancer Res; 2002 May 01; 62(9):2576-82. PubMed ID: 11980652
    [Abstract] [Full Text] [Related]

  • 13. Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence.
    Steiner MS, Zhang Y, Farooq F, Lerner J, Wang Y, Lu Y.
    Cancer Gene Ther; 2000 Mar 01; 7(3):360-72. PubMed ID: 10766342
    [Abstract] [Full Text] [Related]

  • 14. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
    Matsubara S, Wada Y, Gardner TA, Egawa M, Park MS, Hsieh CL, Zhau HE, Kao C, Kamidono S, Gillenwater JY, Chung LW.
    Cancer Res; 2001 Aug 15; 61(16):6012-9. PubMed ID: 11507044
    [Abstract] [Full Text] [Related]

  • 15. Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer.
    Kakinuma H, Bergert ER, Spitzweg C, Cheville JC, Lieber MM, Morris JC.
    Cancer Res; 2003 Nov 15; 63(22):7840-4. PubMed ID: 14633711
    [Abstract] [Full Text] [Related]

  • 16. Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations.
    Suzuki S, Tadakuma T, Asano T, Hayakawa M.
    Cancer Res; 2001 Feb 15; 61(4):1276-9. PubMed ID: 11245419
    [Abstract] [Full Text] [Related]

  • 17. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy.
    Yu DC, Sakamoto GT, Henderson DR.
    Cancer Res; 1999 Apr 01; 59(7):1498-504. PubMed ID: 10197620
    [Abstract] [Full Text] [Related]

  • 18. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma.
    Fukuhara H, Martuza RL, Rabkin SD, Ito Y, Todo T.
    Clin Cancer Res; 2005 Nov 01; 11(21):7886-90. PubMed ID: 16278413
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
    Petrigliano FA, Virk MS, Liu N, Sugiyama O, Yu D, Lieberman JR.
    Prostate; 2009 Sep 15; 69(13):1422-34. PubMed ID: 19489029
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.